Introduction {#S0001}
============

Urinary tract infection (UTI) is one of the most common infectious diseases. UTIs are much more common in women.[@CIT0001],[@CIT0002] It is estimated that almost half of all women will experience at least one UTI in their lifetime.[@CIT0001],[@CIT0002] Recurrent UTIs occur in more than 25% of affected women.[@CIT0003] *Escherichia coli* is the most common pathogen causing UTIs in humans and belongs to the large group of extraintestinal pathogenic *E. coli* (ExPEC).[@CIT0004]--[@CIT0006] ExPEC is the leading cause of community-onset UTIs and nosocomial UTIs.[@CIT0006]

In the last 10 years, the emergence and rapid global spread of *E. coli* sequence type 131 (ST131) with high virulence potential presents a severe threat to public health.[@CIT0007] ST131 is considered to be the predominant ExPEC strain throughout the world.[@CIT0007] Regarding the spread of ST131 among *E. coli* isolates causing UTIs, most studies have focused on extended-spectrum beta-lactamase (ESBL)-producing or fluoroquinolone-resistant (FQ-R) isolates.[@CIT0007] Fewer studies have evaluated the prevalence of ST131 among unselected UTI *E. coli* isolates, with dissimilarities between different subjects and geographic areas.[@CIT0008]--[@CIT0010] ST131 in UTI *E. coli* isolates has been sporadically reported in two recent studies in mainland China,[@CIT0011],[@CIT0012] but this has not yet been investigated systematically. In addition, although the majority of ST131 isolates belong to the O25b:H4 serotype, a small subset of ST131 isolates with the O16:H5 serotype have recently been identified in several countries.[@CIT0013]--[@CIT0016] In China, we first reported O16-ST131 in a previous study, and found that this type was the predominant subset among ST131 fecal *E. coli* isolates.[@CIT0017] However, two recent studies found that O16-ST131 accounted for 33.7% of ST131 among clinical *E. coli* isolates in mainland China,[@CIT0011] and 27.0% of ST131 among urinary *E. coli* isolates in Hong Kong.[@CIT0018] Considering the huge population of China (1.4 billion), more data are urgently needed. Furthermore, women, as a high-risk population, have not yet received the attention they deserve in most studies.[@CIT0008]--[@CIT0012]

Therefore, the aim of the current study was to determine the prevalence of ST131 and molecularly characterize the O25b-ST131 and O16-ST131 subgroups among unselected UTI *E. coli* isolates from women in central China. We also assessed the clinical characteristics and outcomes of infections caused by *E. coli* ST131.

Materials and methods {#S0002}
=====================

Bacterial isolates and clinical data collection {#S0002-S2001}
-----------------------------------------------

This study was conducted at Xiangya Hospital of Central South University, a 3500-bed tertiary care center located in Changsha, central China, with 7500--10,000 daily patient visits. A total of 216 consecutive, non-repetitive *E. coli* clinical isolates from female patients with UTIs, one from each patient, were collected from January 2014 to December 2015. Isolates were recovered from non-duplicate urine samples with significant *E. coli* bacteriuria (colony count \>10^5^ cfu/mL) and pyuria.

The demographic and clinical information of the patients was retrieved retrospectively, and included age, location, history of underlying diseases, use of urinary catheters or central venous catheters, received radiotherapy or chemotherapy within 1 month, corticosteroid or immunosuppressant use within 1 month, recent surgical procedures, treatment with antibiotics and outcomes.

Antimicrobial susceptibility testing {#S0002-S2002}
------------------------------------

Susceptibility testing was performed using the Vitek 2 system (bioMérieux, Marcy-l'Étoile, France) and interpreted in accordance with Clinical and Laboratory Standards Institute (CLSI) criteria.[@CIT0019] ESBL producers were confirmed using the double-disc synergy test.[@CIT0019] Isolates with intermediate susceptibility were considered to be resistant. The resistance score was the number of antimicrobial agents to which the isolate was non-susceptible.[@CIT0017] Multidrug resistance was defined as resistance to three or more antimicrobial categories.[@CIT0017],[@CIT0020]

Phylogenetic group, virulence genotyping, and ST131 detection {#S0002-S2003}
-------------------------------------------------------------

Major *E. coli* phylogenetic groups (A, B1, B2, C, D and E) were determined using PCR.[@CIT0021] The presence of 31 virulence genes was assessed through multiplex PCR and the virulence score was calculated as described previously.[@CIT0022],[@CIT0023] The ST131 lineages and O serotyping were identified as previously described.[@CIT0024]

Molecular characterization of ST131 {#S0002-S2004}
-----------------------------------

Detection of *bla*~CTX-M~ was performed in ST131 isolates through multiplex PCR and sequencing.[@CIT0025],[@CIT0026] *fimH, gyrA* and *parC* subtyping was performed as previously described.[@CIT0027]--[@CIT0029] The screening of plasmid-mediated quinolone resistance (PMQR) determinants \[*qnrA, qnrB, qnrC, qnrS, aac(6ʹ)-Ib-cr* and *qepA*\] was carried out using a multiplex PCR method.[@CIT0030]

Pulsed-field gel electrophoresis (PFGE) {#S0002-S2005}
---------------------------------------

PFGE was performed on all ST131 isolates in accordance with a standardized protocol.[@CIT0031] Banding patterns were analyzed using BioNumerics software (Applied Maths, Sint-Martens-Latem, Belgium) and the Dice similarity coefficient. A dendrogram was constructed in accordance with the unweighted pair group method with arithmetic averages (UPGMA). Isolates were considered to belong to the same PFGE pattern if their Dice similarity index was ≥85%.

Statistical analysis {#S0002-S2006}
--------------------

Categorical variables (clinical information, antimicrobial resistance patterns and virulence traits) were compared between different groups using a χ^2^ or Fisher's exact test, as appropriate. Continuous variables (age, resistance and virulence score) were compared using Student's *t*-test or the Mann-Whitney *U* test. The criterion for statistical significance was *P*\<0.05. All statistical analyses were performed using SPSS Statistics for Windows, version 20.0 (SPSS Inc., Chicago, IL, USA).

Results {#S0003}
=======

Distribution of phylogenetic groups, ST131 and O types {#S0003-S2001}
------------------------------------------------------

Phylogenetic analysis revealed that 100 (46.3%) of the 216 *E. coli* strains belonged to phylogroup B2, 36 (16.7%) to phylogroup D, 29 (13.4%) to phylogroup F, 28 (13.0%) to phylogroup A, 10 (4.6%) to phylogroup B1, 9 (4.2%) to phylogroup C, and 4 (1.8%) to phylogroup E.

Overall, 41 (19.0%) of the 216 *E. coli* strains were identified as ST131, and of these, 27 (65.9%) were from serogroup O25b and 14 (34.1%) from serogroup O16.

Epidemiological and clinical associations of ST131 status and O types {#S0003-S2002}
---------------------------------------------------------------------

The epidemiological and clinical data of the 216 female patients with ST131 and non-ST131 *E. coli* isolates causing UTIs are demonstrated in [Table 1](#T0001){ref-type="table"}. The clinical characteristics of the ST131 group did not differ significantly from the findings for the non-ST131 group, except for the presence of urinary stones (43.9% vs 27.4%, *P*=0.039). In addition, the clinical presentation and outcomes of patients infected with O16-ST131 were similar to those of patients infected with O25b-ST131 isolates.Table 1Epidemiological and clinical data of 216 female patients with ST131 and non-ST131 *E. coli* isolates causing urinary tract infectionVariableNo. (%) of Patients*P*-valueNo. (%) of Patients*P*-valueST131 (n=41)non-ST131 (n=175)O16-ST131 (n=14)O25b-ST131 (n=27)Age (year, mean ± SD)60.2±14.855.3±16.20.07756.0±14.762.4±14.60.189Location Outpatient7 (17.1)25(14.3)0.6513 (21.4)4 (14.8)0.923 Inpatient34 (82.9)150 (85.7)0.65111 (78.6)23 (85.2)0.923Underlying disease Malignancy1 (2.4)18 (10.3)0.1970 (0)1 (3.7)1.000 Hypertension12 (29.3)44 (25.1)0.5873 (21.4)9 (33.3)0.665 Diabetes mellitus12 (29.3)52 (29.7)0.9557 (50.0)5 (18.5)0.082 Coronary artery disease8 (19.5)23 (13.1)0.2953 (21.4)5 (18.5)1.000 Neurological disease11 (26.8)52 (29.7)0.7143 (21.4)8 (29.6)0.849 Chronic kidney disease11 (26.8)46 (26.3)0.9434 (28.6)7 (25.9)1.000 Urinary stones18 (43.9)48 (27.4)0.0399 (64.3)9 (33.3)0.058 Liver cirrhosis3 (7.3)4 (2.3)0.2511 (7.1)2 (7.4)1.000Urinary catheter use12 (29.3)35 (20.0)0.1955 (35.7)7 (25.9)0.771Central venous catheter use3 (7.3)15 (8.6)1.0000 (0)3 (11.1)0.507Corticosteroid or immunosuppressant use within 1 month7 (17.1)48 (27.4)0.1713 (21.4)4 (14.8)0.923Received radiotherapy or chemotherapy within 1 month1 (2.4)15 (8.6)0.3091 (7.1)0 (0)0.341Surgical procedure within prior 30 days13 (31.7)37 (21.1)0.1495 (35.7)8 (29.6)0.966Treatment with antibiotics (≥two categories)22 (53.7)83 (47.4)0.4737 (50.0)15 (55.6)0.73530-day mortality2 (4.9)3 (1.7)0.2411 (7.1)1 (3.7)1.000

Antimicrobial susceptibility associated with ST131 status and O types {#S0003-S2003}
---------------------------------------------------------------------

ST131 isolates showed higher resistance proportions than non-ST131 isolates, except for resistance to nitrofurantoin. This difference was significant for ampicillin, ceftriaxone and ampicillin/sulbactam ([Table 2](#T0002){ref-type="table"}). ST131 accounted for 23.9% of ESBL-producing isolates and 23.0% of the FQ-R isolates, but only 11.0% of non-ESBL-producing isolates and 13.8% of the FQ-susceptible (FQ-S) isolates ([Table 3](#T0003){ref-type="table"}). However, there was no significant difference in the resistance scores of ST131 and non-ST131 isolates.Table 2Prevalence of antimicrobial drug resistance in relation to ST131 status among 216 UTI *E. coli* isolates from womenAntimicrobial resistanceNo. (%) of strains*P*-valueNo. (%) of ST131 strains*P*-valueST131 (n=41)non-ST131 (n=175)O16-ST131 (n=14)O25b-ST131 (n=27)Nitrofurantoin0 (0)33 (18.9)0.0030 (0)0 (0)--Cefazolin33 (80.5)116 (66.3)0.0778 (57.1)25 (92.6)0.021Ampicillin39 (95.1)145 (82.9)0.04713 (92.9)26 (96.3)1.000Ciprofloxacin28 (68.3)94 (53.7)0.0902 (14.3)26 (96.3)0.000Gentamicin17 (41.5)71 (40.6)0.9177 (50.0)10 (37.0)0.424Ceftriaxone32 (78.0)103 (58.9)0.0228 (57.1)24 (88.9)0.053Ampicillin/sulbactam36 (87.8)117 (66.9)0.00812 (85.7)24 (88.9)1.000Imipenem0 (0)1 (0.6)1.0000 (0)0 (0)--Aztreonam20 (48.8)70 (40.0)0.3056 (42.9)14 (51.9)0.585Trimethoprim/sulfamethoxazole21 (51.2)82 (46.9)0.6156 (42.9)15 (55.6)0.440Piperacillin/tazobactam0 (0)7 (4.0)0.4170 (0)0 (0)--Multidrug resistance39 (95.1)135 (77.1)0.00913 (92.9)26 (96.3)1.000ESBLs32 (78.0)102 (58.3)0.0198 (57.1)24 (88.9)0.053Resistance score5.5 (0--8)^a^4.8 (0--10)^a^0.1824.4 (0--6)^a^6.1 (1--8)^a^0.002[^1][^2] Table 3Distribution by resistance group of ST131 among 216 *E. coli* isolates and O25b/O16 subgroups among 41 ST131 isolatesCategoriesESBL (n=134)non-ESBL (n=82)*P*-valueFQ-R (n=122)FQ-S (n=94)*P*-valueST13132 (23.9)9 (11.0)0.01928 (23.0)13 (13.8)0.090 O25b24 (75.0)3 (33.3)0.05326 (92.9)1 (7.7)0.000 O168 (25.0)6 (66.7)0.0532 (7.1)12 (92.3)0.000[^3]

As indicated in [Table 2](#T0002){ref-type="table"}, the O25b-ST131 isolates had a significantly higher prevalence of resistance to cefazolin and ciprofloxacin compared with the O16-ST131 isolates. O25b subgroups accounted for 75.0% and 92.9% of ST131 isolates within ESBL and the FQ-R groups, but only 33.3% and 7.7% of those within non-ESBL-producing and FQ-S groups, respectively. In contrast, O16 subgroups accounted for 66.7% and 92.3% of ST131 isolates within non-ESBL-producing and FQ-S groups, but only 25.0% and 7.1% of those within ESBL and FQ-R groups, respectively ([Table 3](#T0003){ref-type="table"}). Resistance scores were significantly higher for the O25b-ST131 isolates than the O16-ST131 isolates.

Virulence traits associated with ST131 status and O types {#S0003-S2004}
---------------------------------------------------------

The positive rate of virulence genes and virulence scores in ST131 isolates were higher than those in non-ST131 isolates. This difference was significant for *malX, bmaE, iutA, hlyA, kpsM II, traT, afa/draBC, cnf1, iha, ompT, sat, afa FM955459, usp,* *iucD, fyuA,* F10 *papA*, and *fimH* ([Table 4](#T0004){ref-type="table"}). However, the virulence genotypes and virulence scores of the O16-ST131 isolates resembled those of the O25b-ST131 isolates.Table 4Prevalence of virulence traits in relation to ST131 status among 216 UTI *E. coli* isolates from womenVirulence geneNo. (%) of strains*P*-valueNo. (%) of ST131 strains*P*-valueST131 (n=41)non-ST131 (n=175)O16-ST131 (n=14)O25b-ST131 (n=27)Adhesins *fimH*41 (100)145 (82.9)0.00414 (100)27 (100)-- *F10 papA*39 (95.1)46 (26.3)0.00013 (92.9)26 (96.3)1.000 *fimAv~MT78~*0 (0)9 (5.1)0.2940 (0)0 (0)-- *papC*7 (17.1)37 (21.1)0.5602 (14.3)5 (18.5)1.000 *papEF*8 (19.5)42 (24.0)0.5402 (14.3)6 (22.2)0.847 *sfa/focDE*0 (0)5 (2.9)0.5860 (0)0 (0)-- *afa/draBC*11 (26.8)15 (8.6)0.0035 (35.7)6 (22.2)0.580 *afa FM955459*7 (17.1)5 (2.9)0.0013 (21.4)4 (14.8)0.923 *bmaE*4 (9.8)3 (1.7)0.0332 (14.3)2 (7.4)0.882 *gafD*0 (0)1 (0.6)1.0000 (0)0 (0)-- *iha*31 (75.6)64 (36.6)0.0009 (64.3)22 (81.5)0.405Toxins *cdtB*0 (0)0 (0)--0 (0)0 (0)-- *sat*22 (53.7)55 (31.4)0.0072 (14.3)20 (74.1)0.000 *cnf1*11 (26.8)19 (10.9)0.0084 (28.6)7 (25.9)1.000 *hlyA*7 (17.1)5 (2.9)0.0012 (14.3)5 (18.5)1.000Siderophores *iucD*39 (95.1)106 (60.6)0.00013 (92.9)26 (96.3)1.000 *iroN*2 (4.9)47 (26.9)0.0021 (7.1)1 (3.7)1.000 *iutA*39 (95.1)105 (60.0)0.00012 (85.7)27 (100)0.111 *fyuA*32 (78.0)105 (60.0)0.03110 (71.4)22 (81.5)0.734Capsules *kpsM II*36 (87.8)118 (67.4)0.00911 (78.6)25 (92.6)0.425 *kpsM II-K2*2 (4.9)58 (33.1)0.0001 (7.1)1 (3.7)1.000 *kpsM II-K5*19 (46.3)56 (32.0)0.0834 (28.6)15 (55.6)0.100 *kpsM III*0 (0)3 (1.7)1.0000 (0)0 (0)--Miscellaneous *cvaC*0 (0)19 (10.9)0.0570 (0)0 (0)-- *iss*2 (4.9)35 (20.0)0.0210 (0)2 (7.4)0.539 *traT*36 (87.8)105 (60.0)0.00114 (100)22 (81.5)0.224 *ibeA*0 (0)11 (6.3)0.2100 (0)0 (0)-- *malX*39 (95.1)63 (36.0)0.00013 (92.9)26 (96.3)1.000 *usp*40 (97.6)52 (29.7)0.00013 (92.9)27 (100)0.341 *tsh*0 (0)14 (8.0)0.1280 (0)0 (0)-- *ompT*37 (90.2)92 (52.6)0.00013 (92.9)24 (88.9)1.000Virulence score12.5 (7--17)^a^8.2 (1--20)^a^0.00011.6 (7--17)^a^12.9 (11--16)^a^0.072[^4]

ST131 characterization {#S0003-S2005}
----------------------

ESBL-producing *E. coli* ST131 prevalence was 78.0% (32/41). A total of 93.8% (30/32) of the isolates harbored *bla*~CTX-M~. Of the 30 isolates, 15 (50.0%) produced CTX-M-14, 6 (20.0%) CTX-M-55, 4 (13.3%) CTX-M-15, 4 (13.3%) CTX-M-27, and 1 (3.3%) CTX-M-24.

As indicated in [Figure S1](#SD1){ref-type="supplementary-material"}, the majority of the O25b-ST131 isolates belonged to *fimH*30 (25/27, 92.6%), followed by *fimH*41 (n=1) and *fimH*27 (n=1). O25b-*H*30 and O25b-*H*41 isolates were resistant to ciprofloxacin, and possessed a set of four amino acid replacement mutations (*gyrA*1AB Ser-83-Leu, Asp-87-Asn and *parC*1aAB Ser-80-Ile, Glu-84-Val) in the quinolone resistance-determining regions (QRDRs). However, all of the O16-ST131 isolates were found to belong to *fimH*41, and of which, two of the ciprofloxacin-resistant strains harbored three replacement mutations (*gyrA*1AB Ser-83-Leu, Asp-87-Asn and *parC*3A Ser-80-Ile). The *aac(6ʹ)-Ib-cr* gene was found in two ST131 isolates. None of the other types of PMQR determinant were detected.

The PFGE results showed that the 41 ST131 isolates comprised 28 PFGE patterns (defined at ≥85% similarity), the majority of which were grouped into three large clusters with a 70% similarity. These three PFGE clusters accounted for 38 (92.7%, 38/41) isolates ([Figure S1](#SD1){ref-type="supplementary-material"}).

Discussion {#S0004}
==========

The overall rate of the ST131 clone in UTI-associated *E. coli* isolates from women was 19.0%, which is similar to that reported (18.5%) in male and female patients in Hong Kong in 2015 and slightly higher than that observed (15.4%) in the general population in mainland China in 2017.[@CIT0011],[@CIT0018] The high prevalence of this worldwide pandemic clone highlights the necessity to monitor the spread of the highly successful multidrug-resistant ST131 clonal group throughout China. The positivity rate of ESBLs in the ST131 strains was 78.0%, which is higher than that observed (35.1%) in the UK.[@CIT0008] The ST131 isolates were more resistant to ampicillin, ceftriaxone and ampicillin/sulbactam, but more susceptible to nitrofurantoin than the non-ST131 isolates. These results suggest that nitrofurantoin may be effective in treating UTIs caused by *E. coli* ST131.

Similar to previous studies,[@CIT0007],[@CIT0011] we found that O25b-ST131 was the predominant subclone among ST131 isolates. O16-ST131 accounted for a high proportion (34.1%) of the ST131 isolates in the current study, whereas this type accounted for 1% in Australia, 4.3% in Spain, 8% in France and 12% in Japan.[@CIT0007],[@CIT0013]--[@CIT0016] The first report of O16-ST131 was from China in 2015 and occurred in fecal samples from healthy individuals,[@CIT0017] and it has now been identified across China. The distribution of serogroups we observed in the current study is very close to that reported recently from consecutive *E. coli* isolates from various clinical samples in Fuzhou, China.[@CIT0011] This emphasizes the importance of studying the O16 subclone further in this high-incidence country.

Some studies have found that older age was associated with ST131 infection.[@CIT0018],[@CIT0023],[@CIT0032] Although the differences did not reach statistical significance, patients with ST131 isolates were older than those with non-ST131 isolates in the present study. We found for the first time that the presence of urinary stones was significantly associated with patients infected with ST131 isolates, indicating that UTI patients with a history of urinary stones may need to be particularly vigilant against ST131 infections. As has been found in other studies,[@CIT0023],[@CIT0032],[@CIT0033] other clinical characteristics and mortality were similar between the different groups.

Some studies have reported that the ST131 isolates significantly surpassed the non-ST131 isolates in terms of the presence of antimicrobial resistance and/or virulence genes.[@CIT0023],[@CIT0034] The present study demonstrated similar results. Johnson et al considered that the resistance-plus-virulence combination associated with ST131 gave it a fitness advantage in the pathogenic niche.[@CIT0014],[@CIT0034] However, several recent studies using mouse models yielded discordant results as to whether ST131 is more virulent than other *E. coli* strains.[@CIT0014],[@CIT0035],[@CIT0036] We also found that patients with the ST131 isolates with more virulence factors and antimicrobial resistance did not have worse outcomes than patients with non-ST131 isolates, as previous studies reported.[@CIT0023],[@CIT0032] Therefore, further studies are needed to assess the correlation between pathogenic properties and the carriage of virulence genes as well as that between clinical implications and the carriage of virulence genes in ST131 strains.

We found that ST131 isolates mainly carried *fimH*30, in uropathogenic *E. coli* isolates in the current study. This result is in disagreement with our previous study in which *H*41 was the predominant *fimH* allele among ST131 isolates from intestinal commensal *E. coli*.[@CIT0017] Paul et al reported that the tip FimH adhesin of type 1 fimbriae, encoded by the *fimH* gene, was under strong positive selection for functional changes.[@CIT0037] In uropathogenic *E. coli* isolates, the monomannose-specific adherence of the NA114 variant (encoded by the *fimH*30 allele) was higher than the adherence of the SE15 FimH variant (encoded by the *fimH*41 allele).[@CIT0037] Additionally, increased monomannose-specific uroepithelial adhesion is considered to be commonly associated with point FimH mutations in uropathogenic strains of *E. coli*.[@CIT0038] In the current study, we reported for the first time that an O25b-ST131 isolate contained the *fimH*27 allele. This may be because fimH is under selection and probably gained point mutations. Further studies are required to verify this speculation and elucidate the evolution of the *fimH* allele in ST131 isolates.

Consistent with Johnson et al,[@CIT0024] we found that most of the O16-ST131 isolates were susceptible to ciprofloxacin. In contrast, 96.3% of the O25b-ST131 isolates were resistant to ciprofloxacin, suggesting that the O16-ST131 isolates have recently emerged among the fluoroquinolone-susceptible ST131 isolates. The main mechanism of fluoroquinolone resistance in ST131 isolates is amino acid substitutions within the QRDRs of GyrA and ParC, the fluoroquinolone targets.[@CIT0007] Our results also confirm this. The *aac(6ʹ)-Ib-cr* gene had been sporadically detected in ST131 isolates, which is similar to the results of previous studies.[@CIT0007],[@CIT0011] Additionally, the fluoroquinolone-susceptible isolates in the O16-ST131 subgroup were commonly found to have one or two mutations in the QRDRs. With long-term use and exposure to quinolones, these fluoroquinolone-susceptible isolates may be at risk of acquiring drug resistance.[@CIT0039]

A limitation was that certain subgroups, particularly within non-ESBL-producing and FQ-S O25b/O16 sub-lineages, were small, increasing the probability of type II errors.[@CIT0040] Therefore, further multicenter and broad scale studies with larger sample sizes are needed to molecularly characterize these clonal groups in the future.

Conclusion {#S0005}
==========

In summary, to the best of our knowledge, this is the first report to systematically characterize O25b-ST131 and O16-ST131 clonal groups among clinical UTI isolates from women in China. These results are particularly valuable as they are specific to women, a population at high risk of UTIs. Despite the lower ciprofloxacin resistance of the O16-ST131 isolates, these isolates did not exhibit significant differences in virulence genotypes or virulence scores compared with classic O25b-ST131 isolates. The results reveal for the first time that UTI patients with a history of urinary stones may need to be particularly vigilant against ST131 infection.

Supplementary material {#S0008}
======================

Figure S1Pulsed-field gel electrophoresis profiles of XbaI-digested genomic DNA from 41 *E. coli* ST131 isolates. The dendrogram was constructed in accordance with the UPGMA. The broken vertical lines indicate 85% and 70% similarity of PFGE profiles, respectively. Strain number, location, O serogroup, *fimH*, *gyrA*, and *parC* alleles, PFGE patterns and resistance profiles are included. *gyrA*1, wild type; *gyrA*1A, one replacement mutation, Ser-83-Leu; *gyrA*1AB, two replacement mutations, Ser-83-Leu and Asp-87-Asn; *parC*1b, one silent mutation; *parC*3A, a recombined variant containing one replacement mutation Ser-80-Ile; *parC*1aAB, *parC*1a plus the replacement mutations Ser-80-Ile and Glu-84-Val.**Abbreviations:** KZ, cefazolin; AMP, ampicillin; CIP, ciprofloxacin; GEN, gentamicin; CRO, ceftriaxone; A/S, ampicillin/sulbactam; ATM, aztreonam; SXT, trimethoprim/sulfamethoxazole.
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[^1]: **Note:** ^a^The value denotes the mean and range.

[^2]: **Abbreviation:** ESBL, extended-spectrum beta-lactamase.

[^3]: **Abbreviations:** FQ-R, fluoroquinolone-resistant; FQ-S, fluoroquinolone-susceptible; ESBL, extended-spectrum beta-lactamase.

[^4]: **Note:** ^a^The value denotes the mean and range.
